Search

Displaying results 4401 - 4410 of 9670 in total
  1. Drug

    Human umbilical cord blood mononuclear cell-conditioned medium

    go.drugbank.com/drugs/DB15724
    Experimental

    Transplantation with human umbilical cord blood mononuclear cells (HUCBC) has demonstrated promising results in various disease states.

  2. Drug

    Chlorine dioxide

    go.drugbank.com/drugs/DB12453
    Approved

    Chlorine Dioxide has been used in trials studying the treatment of Halitosis.

  3. Drug

    Temocillin

    go.drugbank.com/drugs/DB12343
    ApprovedInvestigationalWithdrawn

    Temocillin has been investigated in Infection, Liver Dysfunction, and Urinary Tract Infection.

  4. Drug

    Pemivibart

    go.drugbank.com/drugs/DB18720
    Investigational

    [L51733] Due to the amino acid substitutions in the Fc region (M435L/N441A), pemivibart has an extended serum half-life.[L51728] … [L50326] It received emergency use authorization (EUA) from the FDA in March 2024 for pre-exposure prophylaxis (PrEP) of COVID-19 in certain high-risk patient populations.

  5. Drug

    FRAX597

    go.drugbank.com/drugs/DB31734
    Experimental

    FRAX597 is a small molecule drug that inhibits the p21-activated kinases (PAKs).[A274673, A274678]

  6. Drug

    Sizofiran

    go.drugbank.com/drugs/DB13128
    Investigational

    It is used as an immunoadjuvant in the treatment of neoplasms, especially tumors found in the stomach. Sizofiran has been used in trials studying the treatment of Cervical Cancer.

  7. Drug

    MF-300

    go.drugbank.com/drugs/DB32060
    Investigational

    As a potential candidate for the treatment of sarcopenia, it has undergone phase 1 studies to evaluate safety, tolerability, and PK/PD characteristics.[A275368,L54983]

  8. Drug

    XL281

    go.drugbank.com/drugs/DB05190
    Investigational

    XL281 is a novel anticancer compound designed to potently inhibit the RAS/RAF/MEK/ERK signaling pathway. … Mutational activation of RAS occurs in about 30 percent of all human tumors, including non-small cell lung, pancreatic, and colon cancer.

  9. Drug

    Elacytarabine

    go.drugbank.com/drugs/DB05494
    Investigational

    Cytarabine has limitations such as minimal uptake in solid tumours and is only used to treat leukaemia. … Elacytarabine is designed to overcome this limitation and has shown considerable uptake in solid tumour cells.

  10. Drug

    Lexibulin

    go.drugbank.com/drugs/DB05147
    Investigational

    CYT997 is an orally available vascular targeting and cytotoxic agent that has proven effective in animal models of a wide range of tumour types including breast, prostate and colon, as well as some leukemias